2. Academic Validation
  3. Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan

Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan

  • Amino Acids. 2021 Jan;53(1):143-147. doi: 10.1007/s00726-020-02921-5.
Declan M Gorman 1,  John Lee 1,  Colton D Payne 1,  Trent M Woodruff 1 2,  Richard J Clark 3
Affiliations

Affiliations

  • 1 School of Biomedical Sciences, The University of Queensland, Brisbane, Australia.
  • 2 Queensland Brain Institute, The University of Queensland, Brisbane, Australia.
  • 3 School of Biomedical Sciences, The University of Queensland, Brisbane, Australia. richard.clark@uq.edu.au.
PMID: 33398524 DOI: 10.1007/s00726-020-02921-5
Abstract

The complement component C5 inhibitory peptide zilucoplan is currently in phase III clinical trials for myasthenia gravis (MG). Despite being at an advanced stage of clinical development, there have been no published reports in the literature detailing its chemical synthesis. In this work, we describe an approach for the chemical synthesis of zilucoplan and validate that the synthesised compound blocks LPS-induced C5a production from human blood.

Keywords

C5; C5a; Complement; Peptide synthesis; Peptides; RA101495; Zilucoplan.

Figures
Products